Incidence of Status Migrainosus in Olmsted County, Minnesota, United States: Characterization and Predictors of Recurrence.
Journal
Neurology
ISSN: 1526-632X
Titre abrégé: Neurology
Pays: United States
ID NLM: 0401060
Informations de publication
Date de publication:
17 01 2023
17 01 2023
Historique:
received:
23
05
2022
accepted:
24
08
2022
pmc-release:
17
01
2024
pubmed:
30
9
2022
medline:
19
1
2023
entrez:
29
9
2022
Statut:
ppublish
Résumé
SM is recognized as a complication of migraine in which pain and/or associated symptoms are unremitting and debilitating for more than 72 hours. The epidemiology of SM in the general population is not known. The aim of this study is to determine the incidence, recurrence rate, and clinical associations of status migrainosus (SM) in care-seeking residents of Olmsted County, Minnesota. The Rochester Epidemiology Project was used to identify the incident cases of SM according to the Between January 1, 2012, and December 31, 2017, 237 incident cases of SM were identified. The median age was 35 (IQR 26-47) years, and 210 (88.6%) were female. A history of chronic migraine was recorded in 82/226 (36.3%) and a history of aura in 76/213 (35.7%). At the time of the incident case, medication reconciliation included a triptan or ergotamine in 127/233 (53.6%) and/or an opioid-containing analgesic in 43/233 (18.5%). The overall age- and sex-adjusted incidence rate was 26.60 per 100,000 [95% CI, 23.21-29.97], with a peak incidence between ages 40 and 49 years. The median (95% CI) attack duration was 5 (4.48-5.42) days. The most frequent triggers were stress (40/237, 16.9%) and too much or too little sleep (27/237, 11.4%). Recurrence occurred in 35/237 (14.8%) at a median of 58 (IQR 23-130) days following the initial attack. In our age- and sex-adjusted multivariable model, too much or too little sleep as a trigger was associated with 12-month risk of recurrence (adjusted OR 3.59 [95% CI 1.58-8.14], Our study provides a population-based estimate of SM incidence. We identified aberrant sleep patterns as a potentially modifiable risk factor for 1-year SM recurrence.
Sections du résumé
BACKGROUND AND OBJECTIVES
SM is recognized as a complication of migraine in which pain and/or associated symptoms are unremitting and debilitating for more than 72 hours. The epidemiology of SM in the general population is not known. The aim of this study is to determine the incidence, recurrence rate, and clinical associations of status migrainosus (SM) in care-seeking residents of Olmsted County, Minnesota.
METHODS
The Rochester Epidemiology Project was used to identify the incident cases of SM according to the
RESULTS
Between January 1, 2012, and December 31, 2017, 237 incident cases of SM were identified. The median age was 35 (IQR 26-47) years, and 210 (88.6%) were female. A history of chronic migraine was recorded in 82/226 (36.3%) and a history of aura in 76/213 (35.7%). At the time of the incident case, medication reconciliation included a triptan or ergotamine in 127/233 (53.6%) and/or an opioid-containing analgesic in 43/233 (18.5%). The overall age- and sex-adjusted incidence rate was 26.60 per 100,000 [95% CI, 23.21-29.97], with a peak incidence between ages 40 and 49 years. The median (95% CI) attack duration was 5 (4.48-5.42) days. The most frequent triggers were stress (40/237, 16.9%) and too much or too little sleep (27/237, 11.4%). Recurrence occurred in 35/237 (14.8%) at a median of 58 (IQR 23-130) days following the initial attack. In our age- and sex-adjusted multivariable model, too much or too little sleep as a trigger was associated with 12-month risk of recurrence (adjusted OR 3.59 [95% CI 1.58-8.14],
DISCUSSION
Our study provides a population-based estimate of SM incidence. We identified aberrant sleep patterns as a potentially modifiable risk factor for 1-year SM recurrence.
Identifiants
pubmed: 36175145
pii: WNL.0000000000201382
doi: 10.1212/WNL.0000000000201382
pmc: PMC10615570
doi:
Substances chimiques
Analgesics, Opioid
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e255-e263Subventions
Organisme : NIA NIH HHS
ID : R33 AG058738
Pays : United States
Informations de copyright
© 2022 American Academy of Neurology.
Références
Neuroepidemiology. 1991;10(5-6):297-307
pubmed: 1798433
Headache. 1983 May;23(3):94-101
pubmed: 6874331
Cephalalgia. 2014 Jul;34(8):633-7
pubmed: 24504530
Headache. 2006 Oct;46(9):1334-43
pubmed: 17040331
Neurology. 1992 Sep;42(9):1657-62
pubmed: 1513451
Mayo Clin Proc. 2012 Dec;87(12):1202-13
pubmed: 23199802
Cephalalgia. 2004 Sep;24(9):707-16
pubmed: 15315526
Headache. 2006 Nov-Dec;46(10):1480-6
pubmed: 17115980
Neurology. 2007 Jan 30;68(5):343-9
pubmed: 17261680
Headache. 2020 May;60(5):878-888
pubmed: 32031255
Headache. 2013 Jan;53(1):81-92
pubmed: 23078241
Headache. 2010 Sep;50(8):1366-70
pubmed: 21044280
Neurology. 2002 Mar 26;58(6):885-94
pubmed: 11914403
Semin Neurol. 2010 Feb;30(1):74-81
pubmed: 20127586
J Clin Med. 2018 Sep 11;7(9):
pubmed: 30208570
Mayo Clin Proc. 2013 Jul;88(7):697-707
pubmed: 23790544
Cephalalgia. 2009 Nov;29(11):1149-55
pubmed: 19830882
Headache. 2015 Jan;55(1):3-20
pubmed: 25600718
Cephalalgia. 2018 Jan;38(1):1-211
pubmed: 29368949
Cephalalgia. 2018 Feb;38(2):304-311
pubmed: 28056534
Headache. 2016 Jun;56(6):911-40
pubmed: 27300483
Am J Epidemiol. 2011 May 1;173(9):1059-68
pubmed: 21430193
JAMA. 2021 Jun 15;325(23):2357-2369
pubmed: 34128998
Headache. 2015 Jan;55(1):21-34
pubmed: 25600719
Headache. 2001 Jul-Aug;41(7):646-57
pubmed: 11554952
Cephalalgia. 2010 May;30(5):599-609
pubmed: 19614702
Headache. 2018 Jul;58(7):964-972
pubmed: 29933509
Cephalalgia. 2020 Jul;40(8):818-827
pubmed: 32162976
Headache. 2016 May;56(5):821-834
pubmed: 27143127
Stat Med. 2000 May 15;19(9):1141-64
pubmed: 10797513
Headache. 2022 Jul;62(7):771-773
pubmed: 35770830
Curr Neurol Neurosci Rep. 2019 Mar 19;19(5):21
pubmed: 30888529